Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized Study to Evaluate the Effectiveness of the Individualization of the Immunological Risk Based on Biomarkers (Disparity of HLA and IFN-γ ELISPOT) to Optimize Immunosuppressor Treatment in Living-donor Renal Recipients

NCT03465397 is registered in ClinicalTrials.gov with ORIOL BESTARD as lead sponsor.

NCT NCT03465397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03465397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized Study to Evaluate the Effectiveness of the Individualization of the Immunological Risk Based on Biomarkers (Disparity of HLA and IFN-γ ELISPOT) to Optimize Immunosuppressor Treatment in Living-donor Renal Recipients
Lead sponsor
ORIOL BESTARD
Phase
Phase 4
Overall status
Unknown status
Start date
November 10, 2017
Completion date
November 30, 2021
Enrollment
164 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant failure and rejection